
XTNT Stock Forecast & Price Target
XTNT Analyst Ratings
Bulls say
Xtant Medical Holdings is a medical technology company with a diverse portfolio of orthobiologics and spinal implant systems that is expected to generate strong revenue growth driven by sales of new products and increasing distributor interest. With a discount to peer valuations, a strong cash position, and opportunities for continued growth and profitability, Xtant presents a promising investment opportunity in the small-cap orthobiologics market.
Bears say
Xtant Medical Holdings is heavily reliant on the US market and faces intense competition in the medical technology industry. Despite its recent acquisition of Dilon Technologies and HEMOBLAST distribution rights, the company is still struggling to generate revenue and improve its gross margins. Additionally, the shift towards a focus on Orthobiologics may not yield significant results in the near term, and the company may need to raise more capital in the future. These risks, combined with a softer procedure environment, may hinder the company's ability to meet its revenue targets and could lead to a decline in share price.
This aggregate rating is based on analysts' research of Xtant Medical Holdings and is not a guaranteed prediction by Public.com or investment advice.
XTNT Analyst Forecast & Price Prediction
Start investing in XTNT
Order type
Buy in
Order amount
Est. shares
0 shares